New Phase 2 SYNAPSE-CMT Study to Test Effects of NMD670 in Charcot-Marie-Tooth Disease Type 1 and 2

Published Date: 21 Nov 2024

The phase 2 trial is expected to include 80 adults with genetically confirmed CMT who will be followed for a 21-day treatment period, using changes in functional assessments as the primary outcome.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot